AHA 2023 | ORBITA-2: PCI vs. Placebo in Stable Angina for Symptom Reduction

In patients with stable chronic angina, percutaneous coronary intervention (PCI) is often conducted to relieve symptoms. However, there is still some uncertainty regarding whether PCI provides superior symptomatic relief compared with a placebo in patients not receiving anti-anginal medication. Researchers conducted a controlled and randomized study in which patients with stable angina discontinued all anti-anginal<a href="https://solaci.org/en/2023/11/14/aha-2023-orbita-2-pci-vs-placebo-in-stable-angina-for-symptom-reduction/" title="Read more" >...</a>

TCT 2023 | The WATCH-TAVR Study

In the TVT registry, around 40% of the patients eligible for transcatheter aortic valve replacement (TAVR) had atrial fibrillation, and there were high levels of adverse events after starting anticoagulant treatment, especially with oral anticoagulants (VKAs), primarily due to bleeding. The purpose of this study was to assess the feasibility, safety, and efficacy of combined<a href="https://solaci.org/en/2023/10/27/tct-2023-the-watch-tavr-study/" title="Read more" >...</a>

Sedación consciente vs anestesia general en el TAVI

Cause of Cardiac Death after TAVR at Present

Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup.  In its early days, TAVR also showed benefits, but<a href="https://solaci.org/en/2023/10/11/cause-of-cardiac-death-after-tavr-at-present/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

TAVI-in-TAVI with Balloon-Expandable Valves

TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address.  While currently uncommon, this is an issue we will probably see more and more<a href="https://solaci.org/en/2023/09/12/tavi-in-tavi-with-balloon-expandable-valves/" title="Read more" >...</a>

estos son los artículos más leídos sobre tavi

Post-TAVI Prosthesis-Patient Mismatch

Prosthesis-patient mismatch (PPM) occurs when the effective orifice area (EOA) after valve placement is significantly smaller compared with the patient’s body surface area (BSA), resulting in an increased transprosthetic residual gradient. The presence of PPM, especially in various surgical series, has been associated with long-term adverse clinical events. In relation to transcatheter aortic valve implantation<a href="https://solaci.org/en/2023/09/06/post-tavi-prosthesis-patient-mismatch/" title="Read more" >...</a>

Predictors and Evolution of Permanent Pacemaker After TAVR with Self-Expanding Valves

Transcatheter aortic valve replacement (TAVR) has shown remarkable benefits and continues to advance towards lower-risk patients and younger ages. However, one of its limitations lies in the demand for a permanent pacemaker (PPM), which during TAVR early stages with self-expanding valves reached 30%. Uncertainty persists regarding the evolution of patients undergoing PPM implantation after TAVR,<a href="https://solaci.org/en/2023/08/17/predictors-and-evolution-of-permanent-pacemaker-after-tavr-with-self-expanding-valves/" title="Read more" >...</a>

implante de la valvula aortica transcateter

SCOPE I Results at 3 Years: ACURATE Neo vs. SAPIEN 3

Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic stenosis. While this has led to the development of new devices with different features, evidence from randomized studies on these new scaffolds is limited. The randomized SCOPE I study (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared<a href="https://solaci.org/en/2023/07/24/scope-i-results-at-3-years-acurate-neo-vs-sapien-3/" title="Read more" >...</a>

Terapia endovascular en stroke: mucha evidencia y pocos operadores entrenados

VASC-OBSERVANT II Substudy: Impact of Vascular Complications after TAVR

At present, transcatheter aortic valve replacement (TAVR) has become increasingly common to treat severe symptomatic aortic stenosis, with the transfemoral approach being the most common access strategy, associated to better outcomes vs. other access sites. Even though vascular complication rates (VC) have dropped given increased operation experience and improved devices, such as the use of<a href="https://solaci.org/en/2023/06/27/vasc-observant-ii-substudy-impact-of-vascular-complications-after-tavr/" title="Read more" >...</a>

EuroPCR 2023 | Intravascular Lithotripsy (IVL) Balloon in the Treatment of Underexpanded Stents

Calcified coronary plaque (CCP) is a challenge for interventional cardiology. Stent underexpansion (SU) commonly associated with CCP could predispose to stent thrombosis or restenosis. Currently, SU in severe CCP can be treated by rotational atherectomy, orbital atherectomy, balloon cutting/scoring, non-compliant high-pressure balloons, or intravascular lithotripsy (IVL). The aim of this meta-analysis was to determine the<a href="https://solaci.org/en/2023/05/22/europcr-2023-intravascular-lithotripsy-ivl-balloon-in-the-treatment-of-underexpanded-stents/" title="Read more" >...</a>

La angina microvascular podría tener gradientes de riesgo

Post PCI Angina: Inevitable or Avoidable?

Predictors of post PCI angina  Among the complications of ischemic cardiomyopathy stenting, those called chronic, with significant functional and mental compromise, might affect patient quality of life. This can be observed in different scenarios, such as instent restenosis and post PCI angina. This kind of complications is associated with anxiety and depression at long term. <a href="https://solaci.org/en/2023/05/09/post-pci-angina-inevitable-or-avoidable/" title="Read more" >...</a>